[go: up one dir, main page]

DK3572517T3 - Humaniserede, universelle letkæde-mus - Google Patents

Humaniserede, universelle letkæde-mus Download PDF

Info

Publication number
DK3572517T3
DK3572517T3 DK19184217.8T DK19184217T DK3572517T3 DK 3572517 T3 DK3572517 T3 DK 3572517T3 DK 19184217 T DK19184217 T DK 19184217T DK 3572517 T3 DK3572517 T3 DK 3572517T3
Authority
DK
Denmark
Prior art keywords
humanized
light chain
universal light
chain mice
mice
Prior art date
Application number
DK19184217.8T
Other languages
English (en)
Inventor
John Mcwhirter
Lynn Macdonald
Sean Stevens
David R Buckler
Andrew J Murphy
Samuel Davis
Karolina A Hosiawa
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK3572517T3 publication Critical patent/DK3572517T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK19184217.8T 2011-08-05 2012-08-03 Humaniserede, universelle letkæde-mus DK3572517T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515374P 2011-08-05 2011-08-05
EP12746246.3A EP2739740B1 (en) 2011-08-05 2012-08-03 Humanized universal light chain mice

Publications (1)

Publication Number Publication Date
DK3572517T3 true DK3572517T3 (da) 2021-06-14

Family

ID=46650953

Family Applications (3)

Application Number Title Priority Date Filing Date
DK12746246T DK2739740T3 (da) 2011-08-05 2012-08-03 Universelle, humaniserede letkæde-mus
DK21157152.6T DK3865581T3 (da) 2011-08-05 2012-08-03 Humaniserede, universelle letkædemus
DK19184217.8T DK3572517T3 (da) 2011-08-05 2012-08-03 Humaniserede, universelle letkæde-mus

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK12746246T DK2739740T3 (da) 2011-08-05 2012-08-03 Universelle, humaniserede letkæde-mus
DK21157152.6T DK3865581T3 (da) 2011-08-05 2012-08-03 Humaniserede, universelle letkædemus

Country Status (27)

Country Link
US (3) US10130081B2 (da)
EP (4) EP4477671A2 (da)
JP (7) JP6510234B2 (da)
CN (2) CN103917650B (da)
AU (5) AU2012294624B2 (da)
BR (1) BR112014002713B1 (da)
CA (1) CA2844070A1 (da)
CY (2) CY1122435T1 (da)
DK (3) DK2739740T3 (da)
ES (3) ES2758051T3 (da)
FI (1) FI3865581T3 (da)
HR (3) HRP20241480T1 (da)
HU (3) HUE068728T2 (da)
IL (5) IL315571A (da)
LT (3) LT2739740T (da)
MX (2) MX357623B (da)
MY (1) MY172718A (da)
NZ (3) NZ781020A (da)
PL (3) PL3865581T3 (da)
PT (3) PT3865581T (da)
RS (3) RS59728B1 (da)
RU (1) RU2664232C2 (da)
SG (3) SG10201914002RA (da)
SI (3) SI3572517T1 (da)
SM (3) SMT202400413T1 (da)
WO (1) WO2013022782A1 (da)
ZA (1) ZA201401006B (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
LT2505654T (lt) 2010-02-08 2016-12-12 Regeneron Pharmaceuticals, Inc. Pelė su įprasta lengvaja grandine
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
EP2597945B1 (en) 2010-07-26 2020-07-22 Trianni, Inc. Transgenic animals and methods of use
PT2601298T (pt) 2010-08-02 2017-01-09 Regeneron Pharma Ratinhos que produzem proteínas de ligação compreendendo domínios vl
RS64280B1 (sr) 2011-02-25 2023-07-31 Regeneron Pharma Adam6 miševi
RU2664232C2 (ru) 2011-08-05 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной универсальной легкой цепью
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
WO2013045916A1 (en) * 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20210113419A (ko) 2011-10-17 2021-09-15 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
ES2720186T3 (es) 2011-12-20 2019-07-18 Regeneron Pharma Ratones con cadenas ligeras humanizadas
NZ793447A (en) * 2012-02-01 2024-05-31 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
SMT201900535T1 (it) 2012-03-16 2019-11-13 Regeneron Pharma Roditori esprimenti sequenze di immunoglobulina sensibile al ph
SI2825036T1 (en) 2012-03-16 2018-08-31 Regeneron Pharmaceuticals, Inc. Light chain antibodies with built-in histidine and genetically modified rodents for their formation
SG11201405164QA (en) 2012-03-16 2014-10-30 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
SG11201407644UA (en) * 2012-06-05 2014-12-30 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain
NZ703689A (en) 2012-06-12 2016-05-27 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
KR101764800B1 (ko) 2013-02-20 2017-08-04 리제너론 파마슈티칼스 인코포레이티드 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물
PT2967013T (pt) * 2013-03-13 2019-04-03 Regeneron Pharma Murganhos que expressam um repertório limitado de cadeia leve de imunoglobulina
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US20150033372A1 (en) * 2013-05-01 2015-01-29 Kymab Limited Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
WO2015112790A2 (en) 2014-01-24 2015-07-30 Children's Medical Center Corporation High-throughput mouse model for optimizing antibody affinities
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
CA2979702A1 (en) * 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
IL257411B2 (en) * 2015-08-24 2024-05-01 Trianni Inc Enhanced production of immunoglobulins
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
AU2017213633B2 (en) 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
CN116004544A (zh) 2016-04-20 2023-04-25 瑞泽恩制药公司 基于使用表达增强性基因座来制备抗体的组合物和方法
JP7324583B2 (ja) 2016-05-20 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 複数のガイドｒｎａを使用して免疫寛容を破綻させるための方法
DK3462853T3 (da) 2016-06-03 2023-04-03 Regeneron Pharma Gnavere, der udtrykker exogen, terminal deoxynukleotidyltransferase
CN118557758A (zh) 2017-02-10 2024-08-30 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
US20190292263A1 (en) 2018-03-24 2019-09-26 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
BR112021023683A2 (pt) 2019-06-05 2022-02-01 Regeneron Pharma Roedor e camundongo geneticamente modificado, embrião de roedor, célula b do roedor ou camundongo geneticamente modificado, hibridoma, população de células b, célula-tronco embrionária, célula de mamífero, métodos de produção de um anticorpo, de uma cadeia pesada, de um domínio variável, de uma coleção de domínios variáveis, de uma cadeia leve, de uma sequência nucleotídica, de um roedor geneticamente modificado e de células es, de geração de um domínio variável e in vitro para gerar uma célula recombinante de roedor, e, vetor de direcionamento
US20220409732A1 (en) 2019-12-02 2022-12-29 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US10994021B1 (en) * 2020-04-11 2021-05-04 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Tetravalent antibody-drug conjugates and use thereof
CA3182925A1 (en) 2020-06-02 2021-12-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
JP2023541216A (ja) * 2020-06-25 2023-09-29 ヒューマブ カンパニー リミテッド ヘテロ接合型トランスジェニック動物
JP2023540808A (ja) 2020-09-11 2023-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗原特異的抗体の同定及び産生
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
JP7579462B2 (ja) 2021-04-20 2024-11-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アルテミンに対するヒト抗体及びその使用方法
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
TW202430028A (zh) * 2023-01-18 2024-08-01 美商基利科學股份有限公司 具有經改變重鏈基因座之嵌合基因轉殖免疫球蛋白小鼠及其製造及使用方法
WO2024173876A1 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
CN117587070B (zh) * 2024-01-19 2024-04-30 北京仁源欣生生物科技有限公司 一种经遗传修饰的非人哺乳动物的制备方法及应用

Family Cites Families (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
ES2146572T3 (es) 1988-09-06 2000-08-16 Xoma Technology Ltd Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ATE140027T1 (de) 1989-12-01 1996-07-15 Pharming Bv Herstellung rekombinanter polypeptide durch rinder und transgene methoden
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
WO1994012215A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
GB9308271D0 (en) 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
US5877396A (en) 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP1149898A2 (en) 1993-12-23 2001-10-31 Infigen, Inc. Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals
GB9401380D0 (en) 1994-01-25 1994-03-23 Pharmaceutical Proteins Ltd Embryonic cell isolation
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP2000512127A (ja) 1996-03-05 2000-09-19 ザ スクリップス リサーチ インスティトゥート ヒトｈｌａ拘束性腫瘍抗原に特異的なｔ細胞受容体をコードする組み換え体
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
ES2384942T3 (es) 1996-12-03 2012-07-16 Amgen Fremont Inc. Anticuerpos humanos que se unen específicamente al TNF alfa
CA2282722A1 (en) 1997-03-06 1998-09-11 Infigen, Inc. Method of cloning animals
CN1203922A (zh) 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
CA2288600C (en) 1997-05-02 2010-06-01 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
JP3992298B2 (ja) 1997-10-03 2007-10-17 中外製薬株式会社 天然ヒト型化抗体
AU760113C (en) 1997-11-18 2004-04-22 Pioneer Hi-Bred International, Inc. Compositions and methods for genetic modification of plants
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
MXPA01010360A (es) 1999-04-15 2004-04-05 Crucell Holland Bv Produccion de proteinas recombinantes en una celula humana.
WO2000073323A2 (en) 1999-05-27 2000-12-07 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP1268832A4 (en) 2000-02-29 2003-04-02 Univ Auburn PRODUCTION OF ANTIBODIES IN TRANSGENIC PLASTIDES
CN101498731A (zh) 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
MXPA03000634A (es) 2000-07-21 2004-12-03 Us Agriculture Metodos para el reemplazo, el desplazamiento y acumulacion de adn en genomas eucarioticos.
MXPA03001915A (es) 2000-08-03 2004-09-10 Therapeutic Human Polyclonals Produccion de anticuerpos humanizados en animales transgenicos.
EP1184458A1 (en) 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002219841A1 (en) 2000-11-16 2002-05-27 Cornell Research Foundation Inc. Vectors for conditional gene inactivation
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
DE10064750A1 (de) 2000-12-22 2002-06-27 Bayer Ag Verfahren zur Herstellung von 1,6-Hexandiolen
ATE464322T1 (de) 2001-01-05 2010-04-15 Pfizer Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
US6961875B2 (en) 2001-03-22 2005-11-01 International Business Machines Corporation Method and apparatus for capturing event traces for debug and analysis
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
US7074611B2 (en) 2001-04-27 2006-07-11 Gie-Cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (Gie) Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof
US7476536B2 (en) 2001-05-11 2009-01-13 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody a light chain gene
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1578917A4 (en) 2001-07-19 2008-01-23 Perlan Therapeutics Inc MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
EP1298207B2 (de) 2001-10-01 2015-12-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
WO2003047336A2 (en) 2001-11-30 2003-06-12 Abgenix, Inc. TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES
GB0130267D0 (en) 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
US20050095712A1 (en) 2002-01-17 2005-05-05 Alberto Martin Mutations caused by activation-induced cytidine deaminase
WO2003059952A1 (en) 2002-01-18 2003-07-24 Inovio As Bispecific antibody dna constructs for intramuscular administration
US7732149B2 (en) 2002-04-26 2010-06-08 Chugai Seiyaku Kabushiki Kaisha Methods of screening agonistic antibodies
WO2003092611A2 (en) 2002-05-03 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of inducing formation of functional and organized lymphatic vessels
KR101143035B1 (ko) 2002-06-14 2012-05-08 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｈＰＡＭ4
CN101962408A (zh) 2002-07-12 2011-02-02 杰斐逊·富特 超人源化抗体
CA2492377C (en) 2002-07-18 2015-02-03 Crucell Holland B.V. Recombinant production of mixtures of antibodies
AR042145A1 (es) 2002-11-27 2005-06-08 Dow Agrociences Llc Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
JP4477579B2 (ja) 2003-01-21 2010-06-09 中外製薬株式会社 抗体の軽鎖スクリーニング方法
AU2004208031B2 (en) 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
JP2006520610A (ja) 2003-03-04 2006-09-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド ハイブリッド不変領域を産生するのに用いるベクター
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
WO2005001087A2 (en) 2003-06-11 2005-01-06 Regeneron Pharmaceuticals, Inc. Methods of modifying genes in eukaryotic cells
US7585668B2 (en) 2003-07-15 2009-09-08 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
US20050153392A1 (en) 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
WO2005038001A2 (en) 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
WO2005070966A2 (en) 2004-01-16 2005-08-04 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US20080060087A1 (en) 2004-02-12 2008-03-06 Davies Collison Cave Modified Cells and Methods of Using Same
CN1560081A (zh) 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
CA2583750C (en) 2004-10-19 2015-11-24 Regeneron Pharmaceuticals, Inc. Methods for generating a rodent having a genetic modification
KR20070090890A (ko) * 2004-10-22 2007-09-06 메디뮨 인코포레이티드 Ｈｍｇｂ1에 대한 고 친화성 항체 및 이의 사용 방법
JP2008517600A (ja) 2004-10-22 2008-05-29 セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド ヒト以外のトランスジェニック動物における内因性免疫グロブリン発現の抑制
WO2006056617A1 (en) 2004-11-26 2006-06-01 Frankgen Biotechnologie Ag Gene trap cassettes for random and targeted conditional gene inactivation
EP1662005A1 (en) 2004-11-26 2006-05-31 FrankGen Biotechnologie AG Enhancer-containing gene trap vectors for random and targeted gene trapping
US20110041370A1 (en) 2005-04-21 2011-02-24 Saint Andre M Face sheet, identification band, and related methods
US20080196112A1 (en) 2005-04-29 2008-08-14 Innate Pharma, S.A. Transgenic Animals and Methods of Making Recombinant Antibodies
EP1896578A4 (en) 2005-05-14 2008-11-05 Univ Fudan PIGGYBAC AS A TOOL FOR GENETIC HANDLING AND ANALYSIS IN VERTEBRATES
DK2002003T3 (da) 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Genvektor omfattende miRNA
ATE416465T1 (de) 2005-06-30 2008-12-15 Borealis Tech Oy Überzug-schicht für energie- oder kommunikationskabel
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AU2006322445B2 (en) 2005-12-05 2011-05-12 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
CA2638117A1 (en) 2006-01-25 2007-08-30 Erasmus University Medical Center Rotterdam Generation of heavy-chain only antibodies in transgenic animals
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
US7462759B2 (en) 2006-02-03 2008-12-09 Pioneer Hi-Bred International, Inc. Brittle stalk 2 gene family and related methods and uses
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DK2041177T3 (da) 2006-06-02 2012-02-27 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
US20090217397A1 (en) 2006-06-12 2009-08-27 Patrick Stern Cre-lox based gene knockdown constructs and methods of use thereof
JP2010501165A (ja) 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
CN102719444B (zh) 2006-09-01 2016-12-14 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
ME00616B (me) 2006-10-02 2011-12-20 Regeneron Pharma Antitijela visokog afiniteta prema humanom il-4 receptoru
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
GB0700194D0 (en) 2007-01-05 2007-02-14 Univ Edinburgh Humanisation of animals
US9043994B2 (en) 2007-03-13 2015-06-02 Massachusetts Institute Of Technology Cre-lox based gene knockdown constructs and methods of use thereof
EP2583550A1 (en) 2007-03-13 2013-04-24 National Jewish Health Methods for generation of antibodies
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
ES2664218T3 (es) 2007-06-01 2018-04-18 Open Monoclonal Technology, Inc Composiciones y procedimientos de inhibición de genes de inmunoglobulinas endógenas y de producción de anticuerpos idiotípicos humanos transgénicos
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
ITMI20071522A1 (it) 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
BRPI0815848A2 (pt) 2007-08-30 2017-06-06 The Burnet Inst composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit.
MX344415B (es) 2007-09-14 2016-12-15 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
CA2708854C (en) 2007-12-14 2017-11-28 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20090271884A1 (en) 2008-03-07 2009-10-29 Regeneron Pharmaceuticals, Inc. ES Cell-Derived Mice From Diploid Host Embryo Injection
EP2271758B1 (en) 2008-04-14 2018-09-12 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2288623B1 (en) 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
ES2906344T3 (es) 2008-06-27 2022-04-18 Merus Nv Animal murino transgénico productor de anticuerpos
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
CA2742968C (en) 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
US8497325B2 (en) 2008-12-15 2013-07-30 Exxonmobil Chemical Patents Inc. Thermoplastic polyolefin blends and films therefrom
KR101711222B1 (ko) 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
US20110305692A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Antigen-binding contructs
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US8808136B2 (en) 2009-05-07 2014-08-19 Volvo Construction Equipment Ab Working machine and a method for operating a working machine
CA2758356C (en) 2009-05-29 2016-07-26 Morphosys Ag A collection of vh and vl pairs having favourable biophysical properties and methods for its use
AU2010265933B2 (en) 2009-06-26 2015-05-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
EP2564695B1 (en) * 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
EP2502993B1 (en) 2009-11-17 2017-07-26 Sanford Applied Biosciences L.L.C. Human artificial chromosome vector
EP2509409B1 (en) 2009-12-10 2016-07-27 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
LT2505654T (lt) 2010-02-08 2016-12-12 Regeneron Pharmaceuticals, Inc. Pelė su įprasta lengvaja grandine
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
NZ605966A (en) 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
US9035128B2 (en) 2010-06-22 2015-05-19 Regeneron Pharmaceuticals, Inc. Hybrid light chain mice
PT2601298T (pt) 2010-08-02 2017-01-09 Regeneron Pharma Ratinhos que produzem proteínas de ligação compreendendo domínios vl
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
RS64280B1 (sr) 2011-02-25 2023-07-31 Regeneron Pharma Adam6 miševi
RU2664232C2 (ru) 2011-08-05 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной универсальной легкой цепью
US20130044257A1 (en) 2011-08-18 2013-02-21 Lattice Energy Technology Corporation Mobile device with side-mounted camera module
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20210113419A (ko) 2011-10-17 2021-09-15 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
ES2720186T3 (es) 2011-12-20 2019-07-18 Regeneron Pharma Ratones con cadenas ligeras humanizadas
NZ793447A (en) 2012-02-01 2024-05-31 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
NZ703689A (en) 2012-06-12 2016-05-27 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
JP2016519568A (ja) 2013-03-13 2016-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 共通軽鎖のマウス
PT2967013T (pt) 2013-03-13 2019-04-03 Regeneron Pharma Murganhos que expressam um repertório limitado de cadeia leve de imunoglobulina

Also Published As

Publication number Publication date
CN107602696B (zh) 2022-05-13
AU2012294624A1 (en) 2013-05-02
IL230766B (en) 2019-10-31
RU2664232C2 (ru) 2018-08-15
EP2739740A1 (en) 2014-06-11
IL315571A (en) 2024-11-01
MX357623B (es) 2018-07-17
PL3572517T3 (pl) 2021-10-04
HRP20241480T1 (hr) 2025-01-03
EP3572517A1 (en) 2019-11-27
HUE055276T2 (hu) 2021-11-29
RU2014108208A (ru) 2015-09-10
DK2739740T3 (da) 2019-12-09
IL297371B1 (en) 2024-10-01
NZ796161A (en) 2024-07-26
JP2020072695A (ja) 2020-05-14
JP2017006146A (ja) 2017-01-12
PT3572517T (pt) 2021-06-23
HUE068728T2 (hu) 2025-01-28
AU2018203592A1 (en) 2018-06-14
JP6886002B2 (ja) 2021-06-16
SMT202100357T1 (it) 2021-07-12
US20130198879A1 (en) 2013-08-01
AU2024205242A1 (en) 2024-08-22
EP3865581B1 (en) 2024-09-25
CY1122435T1 (el) 2021-01-27
AU2018203592B2 (en) 2020-12-10
US20220394959A1 (en) 2022-12-15
IL268413A (en) 2019-09-26
IL273982A (en) 2020-05-31
EP3572517B1 (en) 2021-03-24
IL268413B (en) 2020-05-31
IL297371A (en) 2022-12-01
IL230766A0 (en) 2014-03-31
PT3865581T (pt) 2024-10-04
SG2014007686A (en) 2014-03-28
JP2021118746A (ja) 2021-08-12
AU2012294624B2 (en) 2015-08-13
AU2015255276A1 (en) 2016-01-28
HUE047278T2 (hu) 2020-04-28
DK3865581T3 (da) 2024-10-21
RS66089B1 (sr) 2024-11-29
AU2020277108A1 (en) 2020-12-24
CN103917650A (zh) 2014-07-09
MX2014001454A (es) 2014-06-04
JP6724126B2 (ja) 2020-07-15
SMT202400413T1 (it) 2024-11-15
SMT201900748T1 (it) 2020-03-13
JP2023011882A (ja) 2023-01-24
IL273982B2 (en) 2023-03-01
AU2015255276B2 (en) 2018-02-22
SI3865581T1 (sl) 2024-12-31
LT2739740T (lt) 2019-11-11
HRP20192255T1 (hr) 2020-03-06
ZA201401006B (en) 2015-04-29
JP2024116409A (ja) 2024-08-27
NZ620586A (en) 2015-08-28
RS61946B1 (sr) 2021-07-30
LT3572517T (lt) 2021-04-26
AU2020277108B2 (en) 2024-05-02
SI2739740T1 (sl) 2019-12-31
SG10201914002RA (en) 2020-03-30
US20190133094A1 (en) 2019-05-09
CA2844070A1 (en) 2013-02-14
NZ727084A (en) 2022-08-26
EP2739740B1 (en) 2019-10-02
BR112014002713B1 (pt) 2023-01-17
US11357217B2 (en) 2022-06-14
RS59728B1 (sr) 2020-02-28
JP2014524243A (ja) 2014-09-22
JP7174805B2 (ja) 2022-11-17
CY1124341T1 (el) 2022-07-22
SI3572517T1 (sl) 2021-09-30
EP4477671A2 (en) 2024-12-18
JP7585277B2 (ja) 2024-11-18
CN103917650B (zh) 2017-10-24
ES2758051T3 (es) 2020-05-04
PT2739740T (pt) 2020-01-09
ES2990067T3 (es) 2024-11-28
US10130081B2 (en) 2018-11-20
NZ743520A (en) 2022-12-23
BR112014002713A2 (pt) 2020-10-27
MX2021001074A (es) 2022-06-14
SG10201606158TA (en) 2016-09-29
CN107602696A (zh) 2018-01-19
IL273982B (en) 2022-11-01
FI3865581T3 (fi) 2024-11-02
ES2872081T3 (es) 2021-11-02
MY172718A (en) 2019-12-11
NZ781020A (en) 2023-01-27
JP2019062906A (ja) 2019-04-25
PL3865581T3 (pl) 2024-12-23
LT3865581T (lt) 2024-10-25
JP6510234B2 (ja) 2019-05-08
PL2739740T3 (pl) 2020-06-01
HRP20210916T1 (hr) 2021-09-03
EP3865581A1 (en) 2021-08-18
IL297371B2 (en) 2025-02-01
WO2013022782A1 (en) 2013-02-14
NZ710301A (en) 2017-05-26

Similar Documents

Publication Publication Date Title
IL273982A (en) Humanized mice possess a universal light chain
IL266268B (en) Mice with humanized light chain